WebAlfred Zippelius Science Translational Medicine Vol. 14, NO. 670 09 Nov 2024 Viewpoint What’s next for cancer vaccines by Juraj Adamik Lisa H. Butterfield Science Translational Medicine Vol. 14, NO. 670 09 Nov 2024 Viewpoint Advancing beyond the twists and turns of T cell exhaustion in cancer by Verena van der Heide Etienne Humblin Abishek Vaidya WebFeb 2, 2024 · "The discovery of the role of this gene opens up new approaches for more efficient immunotherapies," summarises Alfred Zippelius. These findings are very promising, as there is a lack of targets ...
Viewpoint Science Translational Medicine AAAS
WebApr 11, 2024 · Immune checkpoint blockade (ICB) has significantly improved the prognosis of cancer patients, but the majority experience limited benefit, evidencing the need for new therapeutic approaches. Upregulation of sialic acid-containing glycans, termed hypersialylation, is a common feature of cancer-associated glycosylation, driving disease … WebMay 27, 2024 · Targeting T cells for cancer immunotherapy commonly fails to generate lasting tumor control. Harnessing additional orchestrators of the immune response against tumors may enhance and broaden clinical benefit. Here, we demonstrate that therapeutic targeting of the IFNγ-IL-12 pathway relies on the amplification of anti-tumoral DC-T cell … prof diarmuid houlihan
Heinz Laubli – Assistant Professor – University of …
WebNov 11, 2024 · Alfred Zippelius & Marcus Vetter. Gynecologic Cancer Center, University Hospital Basel, Basel, Switzerland. Marcus Vetter & Christian Kurzeder. Web1 Cancer Immunology & Biology, Department of Biomedicine, Departments of [email protected] [email protected]. 2 Cancer Immunology & Biology, … WebPeter J. Zippelius. Pete Zippelius is a Partner of Leonard Green & Partners, L.P. (“LGP”) which he joined in 2024. Previously Pete was a Managing Director and Co-Head of North … prof diepold tum